Nektium's botanical ingredient Zynamite granted US patent for brain-enhancing activities
Zynamite is an all-natural evidence-based nootropic and sports performance ingredient, supported by clinical studies.
The United States Patent and Trademark Office has granted Nektium, a research-based branded botanical ingredient manufacturer based in Spain, a patent for its Compositions for Enhancing Brain Activity.
This patent is part of the intellectual property portfolio supporting Nektium's innovative ingredient Zynamite, a caffeine-free botanical ingredient for mental and physical energy. Zynamite is a sustainable, proprietary standardized extract of leaves of a selection of Mangifera indica, the mango tree.
The caffeine-free and doping-free nootropic activities of Zynamite have been appearing in diverse finished product innovations including popular smart supplements and egaming formulations in Japan.
Recognising the fundamental importance of the mind in sports performance, Nektium applied the brain-activating activities of Zynamite to sports formulations, which have been subjected to four double-blind, randomised controlled clinical trials. The positive results of these sports performance and recovery studies have been published in four peer-reviewed papers.
"The currency of the nutraceutical ingredient industry is scientific evidence obtained from double-blind, randomised controlled clinical studies conducted by reputable academic departments and CROs, and published in leading peer-reviewed journals. Nektium has made a major investment in the clinical research backing Zynamite and continues to invest in ongoing clinical studies," said Dr Nigel Gericke, Nektium's Director of Science. "Our intention is to keep building the clinical research base and intellectual property supporting Zynamite as a premium branded ingredient."
Zynamite was first launched at Vitafoods in Geneva and HI Japan in Tokyo in 2018 and at Supply Side West in the USA in 2019.
The nutraceutical industry has already recognized the clinical research and innovation behind Zynamite awarding the ingredient five awards in the last 2 years: the Nutraingredients Award for sports ingredient of the year in 2018, the Nutraingredients Award for research in 2019, the Frost & Sullivan Award for innovation in 2019, and the European Specialised Sports Nutrition Awards for the 2019 best 'free from' ingredient, and the 2019 runner up award for game-changer ingredient of the year.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance